Remedy Pharmaceuticals, Inc. is a privately-held, late clinical stage pharmaceutical company focused on developing and bringing lifesaving treatment to people affected by acute central nervous system edema. Remedy is developing CIRARA for the improvement of functional outcomes by reducing the formation of cerebral edema in patients following Large Hemispheric Infarction (massive ischemic stroke affecting the total or sub-total territory of the middle cerebral artery). There are currently no therapeutic approaches targeted at reducing the development of edema early after Large Hemispheric Infarction, and CIRARA is scheduled to begin a Phase 3 study in 2017 with the aim of meaningfully reducing the high mortality and morbidity of this disease.

http://www.remedypharmaceuticals.com/